Corbevax, Covovax, Molnupiravir approved for restricted emergency use against COVID-19 | NEW DELHI: The Central Government has given approval for two more covid vaccines and one pill on Tuesday. The two latest vaccines approved by drug regulator CDSCO are Corbevax and Covovax. The anti-viral drug called Molnupiravir is a pill that can be used only in an emergency.

Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare has given emergency use authorization approval to COVID19 vaccines Covovax & Corbevax and Anti-viral drug Molnupiravir, Health Minister Mansukh Mandaviya tweeted. The CDSCO recommended granting emergency use authorisation (EUA) to the COVID-19 vaccines Covovax and Corbevax with certain conditions.

Congratulations India 🇮🇳

Further strengthening the fight against COVID-19, CDSCO, @MoHFW_INDIA has given 3 approvals in a single day for:

- CORBEVAX vaccine
- COVOVAX vaccine
- Anti-viral drug Molnupiravir

For restricted use in emergency situation. (1/5)
— Dr Mansukh Mandaviya (@mansukhmandviya) December 28, 2021

- The Minister stated that the CORBEVAX vaccine is India's 1st indigenously developed RBD protein sub-unit vaccine against COVID19, made by Hyderabad-based firm Biological-E Ltd.

- While the Nanoparticle Vaccine, COVOVAX, will be manufactured by Pune-based firm Serum Institute of India.

-Molnupiravir is an antiviral drug, manufactured in the country by 13 companies for restricted use under emergency situation for the treatment of adult patients with COVID-19 and who have high risk of progression of the disease, he said.

All these approvals will further strengthen the global fight against the pandemic and our Pharma Industries are an asset for the entire world, the Minister stated.

The number of Covid vaccines which have received emergency use authorisation in the country has now increased to eight. Six COVID-19 vaccines — Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Zydus Cadila’s ZyCoV-D, Russia’s Sputnik V, and the US-made Moderna and Johnson and Johnson — had already received EUA from the Indian drug regulator earlier.

Also Read: AP to Prioritise Elderly, People With Chronic Diseases For Booster Dose